Aegerion Pharmaceuticals, Inc. Acknowledges the National Lipid Association's Revised Guidelines for the Treatment of Familial Hypercholesterolemia

CAMBRIDGE, Mass., April 14, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, today acknowledged the publication of the National Lipid Association's (NLA) guidelines for the screening, diagnosis and treatment of familial hypercholesterolemia (FH). There are six articles in total published in the April 2011 Journal of Clinical Lipidology summarizing the consensus opinion of the National Lipid Association's Expert Panel on Familial Hypercholesterolemia with respect to the prevalence of the disease and recommended clinical criteria for diagnosis and treatment of pediatric and adult patient populations across the spectrum of FH severity.